
James W Freston MD PhD, FAGA
Esophagus Disease, Hepatology & Liver Transplantation
Emeritus Professor of Medicine and Boehringer Ingelheim Chair of Clinical Pharmacology. Consultant to FDA, NIH, pharmaceutical and medical device industries
Join to View Full Profile
263 Farmington AveFarmington, CT 06030
Phone+1 860-679-3238
Fax+1 860-679-1217
Dr. Freston is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Utah HealthResidency, Internal Medicine, 1961 - 1965
- University of Utah School of MedicineClass of 1961
- Weber State UniversityUndergraduate, 1954 - 1957
Certifications & Licensure
- CT State Medical License 1980 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Julius Freidenwald Medal for Outstanding Contributions to Gastroenterology American Gastroenterological Association (AGA), 2007
- Fellow (AGAF) American Gastroenterological Association, 2007
- Distinguished Alumnus Award University of Utah, 2006
- Join now to see all
Publications & Presentations
PubMed
- 18 citationsClinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical ...David H Alpers, James H Lewis, Christine M Hunt, James W Freston, Vicente E Torres
American Journal of Kidney Diseases. 2023-03-01 - 21 citationsConsensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chroni...William R. Treem, Melissa Palmer, I. Lonjon-Domanec, Daniel Seekins, Lara Dimick-Santos
Drug Safety. 2021-02-01 - 19 citationsReal-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.Daniel C. Beachler, Cynthia de Luise, Aziza Jamal-Allial, Ruihua Yin, Devon H. Taylor
BMC Cancer. 2021-01-25
Journal Articles
- Liver Complications Following Treatment of Hematologic Malignancy with Anti‐cd22‐Calicheamicin (Inotuzumab Ozogamicin)James W Freston, Laurie D DeLeve, George B McDonald, Hepatology
- Clinical and histological features of fluoroquinolone-induced liver injuryEric S. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rachon J, Kleiner DE, Hayashi PH, Clinical Gastroenterology and Hepatology, 1/1/2011
- A Causality assessment in drug-induced liver disease using a structured expert opinion process: Comparison to the Roussel Unclaf causality assessment methodRockey DC, Seeff, LB, Rochon J, Freston J. Chalasani N, Bonacine M, Fontana RR, Hayashi P, Hepatology, 1/1/2010
- Join now to see all
Books/Book Chapters
Other
- Use and limitations of the RUCAM in hepatotoxicity adjudication.Freston JW
1/1/2006 - Method for predicting the onset or change of a medical condition.DC Trost, JW Freston, J Ostroff, US Patent App. 10/968,675, 2004 - Google Patents US 20050119534A1 (19) United States (12) Patent Ap
6/2/2005 - Digestive Diseases Self-Education Program. A core curriculum and self assessment in gastroenterology and hepatology. CD-ROM, syllabus, atlas, and exam.Freston JW, A CME Program, American Gastroenterological Association
1/1/1998 - Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: